Vessel Wall Changes on Serial High-Resolution MRI and the Use of Cilostazol in Patients With Adult-Onset Moyamoya Disease
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background and Purpose The natural course of adult-onset moyamoya disease (MMD) is unknown, and there is no medical treatment that halts its progression. We hypothesized that progressive shrinkage of large intracranial arteries occurs in adult-onset MMD, and that cilostazol inhibits this process. Methods Serial high-resolution magnetic resonance imaging (HR-MRI) was performed on 66 patients with MMD: 30 patients received cilostazol, 21 received other antiplatelets, and 15 received no antiplatelets or had poor compliance to them. Serial HR-MRI was performed (interval between MRI scans: 29.67±18.02 months, mean±SD), and changes in outer diameter, luminal stenosis, and vascular enhancement were measured. Factors affecting HR-MRI changes were evaluated, including vascular risk factors and the ring finger protein 213 gene variant. Results The progression of stenosis to occlusion, recurrent ischemic stroke, and the development of new stenotic segments were observed in seven, seven, and three patients, respectively. Serial HR-MRI indicated that the degree of stenosis increased with negative remodeling (outer diameter shrinkage). Patients who received cilostazol presented significantly larger outer diameters and lower degrees of stenosis compared with other groups (p=0.005 and p=0.031, respectively). After adjusting for clinical and genetic factors, only cilostazol use was independently associated with negative remodeling (odds ratio=0.29, 95% confidence interval=0.10–0.84, p=0.023). While vascular enhancement was observed in most patients (61 patients), the progression of enhancement or the occurrence of new vascular enhancement was rarely observed on follow-up HR-MRI (6 and 1 patients, respectively). Conclusions Adult-onset MMD induces progressive shrinkage of large intracranial arteries, which cilostazol treatment may prevent. Further randomized clinical trials are warranted.
Abstract
Background and Purpose The natural course of adult-onset moyamoya disease (MMD) is unknown, and there is no medical treatment that halts its progression. We hypothesized that progressive shrinkage of large intracranial arteries occurs in adult-onset MMD, and that cilostazol inhibits this process. Methods Serial high-resolution magnetic resonance imaging (HR-MRI) was performed on 66 patients with MMD: 30 patients received cilostazol, 21 received other antiplatelets, and 15 received no antiplatelets or had poor compliance to them. Serial HR-MRI was performed (interval between MRI scans: 29.67±18.02 months, mean±SD), and changes in outer diameter, luminal stenosis, and vascular enhancement were measured. Factors affecting HR-MRI changes were evaluated, including vascular risk factors and the ring finger protein 213 gene variant. Results The progression of stenosis to occlusion, recurrent ischemic stroke, and the development of new stenotic segments were observed in seven, seven, and three patients, respectively. Serial HR-MRI indicated that the degree of stenosis increased with negative remodeling (outer diameter shrinkage). Patients who received cilostazol presented significantly larger outer diameters and lower degrees of stenosis compared with other groups (p=0.005 and p=0.031, respectively). After adjusting for clinical and genetic factors, only cilostazol use was independently associated with negative remodeling (odds ratio=0.29, 95% confidence interval=0.10–0.84, p=0.023). While vascular enhancement was observed in most patients (61 patients), the progression of enhancement or the occurrence of new vascular enhancement was rarely observed on follow-up HR-MRI (6 and 1 patients, respectively). Conclusions Adult-onset MMD induces progressive shrinkage of large intracranial arteries, which cilostazol treatment may prevent. Further randomized clinical trials are warranted.
참고문헌 (24)
- Ihara M, "Moyamoya disease : diagnosis and interventions", Lancet Neurol, 21, pp.747~758 (2022)
- Ryoo S, "Differential vascular pathophysiologic types of intracranial atherosclerotic stroke : a high-resolution wall magnetic resonance imaging study", Stroke, 46, pp.2815~2821 (2015)
- Kim YJ, "High resolution MRI difference between moyamoya disease and intracranial atherosclerosis", Eur J Neurol, 20, pp.1311~1318 (2013)
- Kaku Y, "Outer-diameter narrowing of the internal carotid and middle cerebral arteries in moyamoya disease detected on 3D constructive interference in steady-state MR image : is arterial constrictive remodeling a major pathogenesis?", Acta Neurochir(Wien), 154, pp.2151~2157 (2012)
- Huang Y, "Cilostazol as an alternative to aspirin after ischaemic stroke : a randomised, doubleblind, pilot study", Lancet Neurol, 7, pp.494~499 (2008)
- Shinohara Y, "Cilostazol for prevention of secondary stroke(CSPS 2) : an aspirin-controlled, double-blind, randomised non-inferiority trial", Lancet Neurol, 9, pp.959~968 (2010)
- Toyoda K, "Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan : a multicentre, open-label, randomised controlled trial", Lancet Neurol, 18, pp.539~548 (2019)
- Oki K, "Trends of antiplatelet therapy for the management of moyamoya disease in Japan : results of a nationwide survey", J Stroke Cerebrovasc Dis, 27, pp.3605~3612 (2018)
- Seo WK, "Association of antiplatelet therapy, including cilostazol, with improved survival in patients with moyamoya disease in a nationwide study", J Am Heart Assoc, 10, pp.e017701~ (2021)
- Research Committee on the Pathology and Treatment of Spontaneous Occlusion of the Circle of Willis, "Guidelines for diagnosis and treatment of moyamoya disease(spontaneous occlusion of the circle of Willis)", Neurol Med Chir(Tokyo), 52, pp.245~266 (2012)
- Fujimura M, "Current status of revascularization surgery for moyamoya disease : special consideration for its ‘internal carotidexternal carotid(IC-EC)conversion’ as the physiological reorganization system", Tohoku J Exp Med, 236, pp.45~53 (2015)
- Choi EH, "Ring finger protein 213 variant and plaque characteristics, vascular remodeling, and hemodynamics in patients with intracranial atherosclerotic stroke : a high-resolution magnetic resonance imaging and hemodynamic study", J Am Heart Assoc, 8, pp.e011996~ (2019)
- Yeon JY, "The prediction of contralateral progression in children and adolescents with unilateral moyamoya disease", Stroke, 42, pp.2973~2976 (2011)
- Sato Y, "Characteristics of moyamoya disease based on national registry data in Japan", Stroke, 50, pp.1973~1980 (2019)
- Kuroda S, "Radiological findings, clinical course, and outcome in asymptomatic moyamoya disease : results of multicenter survey in Japan", Stroke, 38, pp.1430~1435 (2007)
- Cho WS, "The natural clinical course of hemodynamically stable adult moyamoya disease", J Neurosurg, 122, pp.82~89 (2015)
- 방오영, "The Pathophysiology of Moyamoya Disease: An Update", 대한뇌졸중영문학회지, 18(1), pp.12~20 (2016), 대한뇌졸중학회
- iodoamphetamine single-photon emission computed tomography, "Neurosurgery", 2011, 957~965
- Fujimura M, "Moyamoya disease", Front Neurol Neurosci, 40, pp.204~220 (2016)
- Dlamini N, "Childhood moyamoya : looking back to the future", Pediatr Neurol, 91, pp.11~19 (2019)
- Kim DY, "Infarct pattern and collateral status in adult moyamoya disease : a multimodal magnetic resonance imaging study", Stroke, 48, pp.111~116 (2017)
- Kwon SU, "Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis : the multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis", Stroke, 36, pp.782~786 (2005)
- Kawabe-Yako R, "Cilostazol activates function of bone marrow-derived endothelial progenitor cell for re-endothelialization in a carotid balloon injury model", PLoS One, 6, pp.e24646~ (2011)
- Kim MJ, "Cilostazol inhibits vascular smooth muscle cell growth by downregulation of the transcription factor E2F", Hypertension, 45, pp.552~556 (2005)